Number of Companies Investing in Neuroscience Drug Discovery

Total Page:16

File Type:pdf, Size:1020Kb

Number of Companies Investing in Neuroscience Drug Discovery 10/26/2015 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke NINDS Office of Translational Research: New Programs to Rajesh Ranganathan, PhD Support Therapy and Director, Office of Translational Research Device Discovery and NINDS Development [email protected] July 2015 Number of companies investing in Neuroscience drug discovery 2 1 10/26/2015 Number of companies investing in Neuroscience drug discovery 3 CNS drug discovery portfolio 4 2 10/26/2015 5 6 3 10/26/2015 Ecosystem is pursuing new models – eliminate silos Academia Biotech Pharma Project 1 Project 2 Project 3 Carsten Skarke and Garret A. FitzGerald, Science Translational Medicine April 2010 7 What should NINDS’s role be in this changing climate? 8 4 10/26/2015 Appropriations (Dollars in Thousands) FY 2011 FY 2012 FY 2013 FY2014 FY 2015 NINDS $1,622,003 $1,624,830 $1,533,795 $1,588,904 $1,604,607 NINDS % Base 0.2% -5.6% 3.6% 1.0% Change NIH $30,687,290 $30,860,387 $29,151,462 $30,150,853 $30,311,349 NIH % Change Base 0.6% -5.5% 3.4% 0.5% Average IC increase was 0.31% NINDS and NIMH each received increase of $12.3 M for BRAIN Initiative Funding up to 14 th percentile 9 Total NINDS Extramural Grants Budget 1.6 NINDS Extramural 1.4 1.2 adjusted to 1995 1 dollars 0.8 with ARRA Billions) 0.6 0.4 with ARRA-- 0.2 adjusted to 1995 NINDS Extramural Grant Dollars (in (in Dollars Grant Extramural NINDS dollars 0 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 10 5 10/26/2015 FY 2013 Taxpayer Investment in Neuroscience Now Exceeds Cancer 7 6 5.274 5.34 4.887 5 4 3 Dollars in Billions (FY 2013) BillionsinDollars(FY 2 1 0 Cancer Neurosciences Infectious Diseases Research Category Source: http://report.nih.gov/categorical_spending.aspx 11 NIH Neuroscience Research Other Includes: NIDDK NIAAA NCI FIC 0.03% OTHER 3% 3% 3% TYPE 1 0.01% NINDS 10% NLM 0.02% 27% NIGMS NCMHD 0.05% 3% NCATS 0.14% NHLBI NHGRI 0.26% 4% NIDCR 0.52% NIMH NINR 0.52% 15% NICHD NIAMS 0.59% NIA NEI 4% NCCAM 0.60% 8% 8% NIDCD NIAID 1.06% 4% NIBIB 1.22% NIEHS 1.50% NIDA RMAP 1.64% 8% OD 2.14% Source: http://report.nih.gov/categorical_spending.aspx 12 6 10/26/2015 The Problem Unmet need in hundreds of neurological disorders Chronic Orthostatic Intolerance Globoid Cell Leukodystrophy Metachromatic Leukodystrophy Pinched Nerve Tabes Dorsalis Absence of the Septum Pellucidum Chronic Pain Glossopharyngeal Neuralgia Microcephaly Piriformis Syndrome Tardive Dyskinesia Acquired Epileptiform Aphasia Cockayne Syndrome Type II Guillain-Barre Syndrome Migraine Pituitary Tumors Tarlov Cysts Acute Disseminated Coffin Lowry Syndrome Hallervorden-Spatz Disease Miller Fisher Syndrome Polymyositis Tay-Sachs Disease Encephalomyelitis COFS Head Injury Mini-Strokes Pompe Disease Temporal Arteritis ADHD Coma and Persistent Vegetative Headache Mitochondrial Myopathies Porencephaly Tethered Spinal Cord Syndrome Adrenoleukodystrophy State Hemicrania Continua Mobius Syndrome Postherpetic Neuralgia Thomsen Disease Agenesis of the Corpus Callosum Complex Regional Pain Syndrome Hemifacial Spasm Monomelic Amyotrophy Postinfectious Encephalomyelitis Thoracic Outlet Syndrome Agnosia Congenital Facial Diplegia Hemiplegia Alterans Motor Neuron Diseases Post-Polio Syndrome Thyrotoxic Myopathy Aicardi Syndrome Congenital Myasthenia Hereditary Neuropathies Moyamoya Disease Postural Hypotension Tic Douloureux AIDS - Neurological Complications Congenital Myopathy Hereditary Spastic Paraplegia Mucolipidoses Postural Orthostatic Tachycardia Todd's Paralysis Alexander Disease Congenital Vascular Cavernous Heredopathia Atactica Mucopolysaccharidoses Syndrome Tourette Syndrome Alpers' Disease Malformations Polyneuritiformis Multifocal Motor Neuropathy Postural achycardia Syndrome Transient Ischemic Attack Alternating Hemiplegia Corticobasal Degeneration Herpes Zoster Multi-Infarct Dementia Primary Dentatum Atrophy Transmissible Spongiform Alzheimer's Disease Cranial Arteritis Herpes Zoster Oticus Multiple Sclerosis Primary Lateral Sclerosis Encephalopathies Amyotrophic Lateral Sclerosis Craniosynostosis Hirayama Syndrome Multiple System Atrophy Prion Diseases Transverse Myelitis Anencephaly Creutzfeldt-Jakob Disease Holoprosencephaly Multiple System Atrophy with Progressive Hemifacial Atrophy Traumatic Brain Injury Aneurysm Cumulative Trauma Disorders HTLV-1 Associated Myelopathy Orthostatic Hypotension Progressive Locomotor Ataxia Tremor Angelman Syndrome Cushing's Syndrome Huntington's Disease Muscular Dystrophy Progressive Multifocal Trigeminal Neuralgia Angiomatosis Cytomegalic Inclusion Body Disease Hydranencephaly Myasthenia - Congenital Leukoencephalopathy Tropical Spastic Paraparesis Anoxia (CIBD) Hydrocephalus Myasthenia Gravis Progressive Sclerosing Tuberous Sclerosis Aphasia Cytomegalovirus Infection Hydrocephalus - Normal Pressure Myelinoclastic Diffuse Sclerosis Poliodystrophy Vascular Erectile Tumor Arteriovenous Malformation Dancing Eyes-Dancing Feet Hydromyelia Myoclonic Encephalopathy of Progressive Supranuclear Palsy Vasculitis including Temporal Asperger Syndrome Syndrome Hypercortisolism Infants Pseudotumor Cerebri Arteritis Ataxia Dandy-Walker Syndrome Hypersomnia Myoclonus Ramsay Hunt Syndrome Von Economo’s Disease Ataxia Telangiectasia Dawson Disease Hypertonia Myopathy Ramsay Hunt Syndrome I (formerly Von Hippel-Lindau Disease (VHL) Ataxias and De Morsier's Syndrome Hypotonia - Infantile Myopathy - Congenital known as) Von Recklinghausen's Disease Cerebellar/Spinocerebellar Deep Brain Stimulation for Hypoxia Myopathy - Thyrotoxic Ramsay Hunt Syndrome II Wallenberg's Syndrome Degeneration Parkinson's Disease Immune-Mediated Myotonia Rasmussen's Encephalitis Werdnig-Hoffman Disease Attention Deficit-Hyperactivity Dejerine-Klumpke Palsy Encephalomyelitis Myotonia Congenita Reflex Sympathetic Dystrophy Wernicke-Korsakoff Syndrome Disorder Dementia - Multi-Infarct Inclusion Body Myositis Narcolepsy Syndrome West Syndrome Autism Dementia - Subcortical Incontinentia Pigmenti Neuroacanthocytosis Refsum Disease Whiplash Autonomic Dysfunction Dementia With Lewy Bodies Infantile Hypotonia Neurodegeneration with Brain Iron Refsum Disease - Infantile Whipple's Disease Back Pain Dentate Cerebellar Ataxia Infantile Phytanic Acid Storage Accumulation Repetitive Motion Disorders Williams Syndrome Barth Syndrome Dentatorubral Atrophy Disease Neurofibromatosis Repetitive Stress Injuries Wilson's Disease Batten Disease Dermatomyositis Infantile Refsum Disease Neuroleptic Malignant Syndrome Restless Legs Syndrome X-Linked Spinal and Bulbar Behcet's Disease Developmental Dyspraxia Infantile Spasms Retrovirus-Associated Myelopathy Muscular Atrophy Bell's Palsy Devic's Syndrome Inflammatory Myopathy Neurological Complications of AIDS Rett Syndrome Zellweger Syndrome Benign Essential Blepharospasm Diabetic Neuropathy Intestinal Lipodystrophy Neurological Complications Of Lyme Reye's Syndrome Benign Focal Amyotrophy Diffuse Sclerosis Intracranial Cysts Disease Riley-Day Syndrome Benign Intracranial Hypertension Dysautonomia Intracranial Hypertension Neurological Manifestations of Sacral Nerve Root Cysts Bernhardt-Roth Syndrome Dysgraphia Isaac's Syndrome Pompe Disease Saint Vitus Dance Binswanger's Disease Dyslexia Joubert Syndrome Neurological Sequelae Of Lupus Salivary Gland Disease Blepharospasm Dysphagia Kearns-Sayre Syndrome Neuromyelitis Optica Sandhoff Disease Bloch-Sulzberger Syndrome Dyspraxia Kennedy's Disease Neuromyotonia Schilder's Disease Brachial Plexus Birth Injuries Dyssynergia Cerebellaris Kinsbourne syndrome Neuronal Ceroid Lipofuscinosis Schizencephaly Brachial Plexus Injuries Myoclonica Kleine-Levin Syndrome Neuronal Migration Disorders Seizure Disorder Bradbury-Eggleston Syndrome Dyssynergia Cerebellaris Klippel-Feil Syndrome Neuropathy - Hereditary Septo-Optic Dysplasia Brain and Spinal Tumors Progressiva Klippel-Trenaunay Syndrome (KTS) Neurosarcoidosis Shaken Baby Syndrome Brain Aneurysm Dystonias Klüver-Bucy Syndrome Neurotoxicity Shingles Brain Injury Early Infantile Epileptic Korsakoff's Amnesic Syndrome Nevus Cavernosus Shy-Drager Syndrome Brown-Sequard Syndrome Encephalopathy Krabbe Disease Niemann-Pick Disease Sjogren's Syndrome Bulbospinal Muscular Atrophy Empty Sella Syndrome Kugelberg-Welander Disease Normal Pressure Hydrocephalus Sleep Apnea Canavan Disease Encephalitis and Meningitis Kuru Occipital Neuralgia Sleeping Sickness Carpal Tunnel Syndrome Encephalitis Lethargica Lambert-Eaton Myasthenic Occult Spinal Dysraphism Sequence Soto's Syndrome WWW.NINDS.NIH.GOV Causalgia Encephaloceles Syndrome Ohtahara Syndrome Spasticity Cavernomas Encephalopathy Landau-Kleffner Syndrome Olivopontocerebellar Atrophy Spina Bifida Cavernous Angioma Encephalotrigeminal Angiomatosis Lateral Femoral Cutaneous Nerve Opsoclonus Myoclonus Spinal Cord Infarction Cavernous Malformation Epilepsy Entrapment Orthostatic Hypotension Spinal Cord Injury Central Cervical Cord Syndrome Erb-Duchenne and Dejerine- Lateral Medullary Syndrome O'Sullivan-McLeod Syndrome Spinal Cord Tumors Central Cord Syndrome Klumpke Palsies Learning Disabilities Overuse Syndrome Spinal Muscular Atrophy Central Pain Syndrome Erb's Palsy Leigh's Disease Pain - Chronic Spinocerebellar Atrophy Cephalic Disorders Fabry's Disease Lennox-Gastaut Syndrome Pantothenate Kinase-Associated Spinocerebellar Degeneration Cerebellar Degeneration Fahr's Syndrome Lesch-Nyhan Syndrome Neurodegeneration Steele-Richardson-Olszewski Cerebellar Hypoplasia
Recommended publications
  • Thyrotoxic Myopathy Muscle Strength of Proximal Muscle Graded at 4/5 on M.R.C
    Arch Dis Child: first published as 10.1136/adc.49.12.968 on 1 December 1974. Downloaded from 968 Short reports marked Gower's manoeuvre on getting up from the floor. Thyrotoxic myopathy Muscle strength of proximal muscle graded at 4/5 on M.R.C. scale. The distal muscles were of normal A variety of neuromuscular disorders has been strength. The reflexes were normal. described in adults in association with overactivity of Bone age 6 years. Protein bound iodine (PBI) 13 6 the thyroid (Millikan and Haines, 1953; Ramsay, pLg/100 ml (normal 3 * 8-8 *0); total thyroxine 17 * 7 itg/100 1966; Engel, 1972). The most common of these ml (normal 4-5-13-6); T3 uptake 77%; LATS not disorders is a chronic myopathy, characterized by detectable. IgG and IgM normal, but IgA low at 12 muscular atrophy and weakness involving pre- mg/100 ml (normal 73-250). Thyroglobulin antibodies dominantly proximal muscles (Adams and Rosman, negative by electroprecipitin test, the tanned red cell titre positive to 1/25. Thyroid microsome immuno- 1971). The myopathic symptoms may precede the fluorescence, antinuclear factor, mitochondrial antibody, symptoms of thyrotoxicosis by many months, and smooth muscle antibody, and gastric parietal cells were the atrophy and weakness may be so pronounced all negative. that it suggests a diagnosis of progressive muscular Creatine phosphokinase (CPK) 16 mIU/ml (normal up atrophy or a limb-girdle type muscular dystrophy. to 140). Electrodiagnostic studies showed normal motor Less commonly, myasthenia gravis and periodic nerve conduction. Concentric needle electrode paralysis may be associated with thyrotoxicosis.
    [Show full text]
  • Therapeutic Class Brand Name P a Status Generic
    P A Therapeutic Class Brand Name Status Generic Name Strength Form Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 250MG/5ML ORAL SUSP Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET DR Absorbable Sulfonamides BACTRIM DS SULFAMETHOXAZOLE/TRIMETHO 800-160MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE 500MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML ORAL SUSP Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML SYRUP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 200-40MG/5 ORAL SUSP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 400-80MG TABLET Absorbable Sulfonamides SULFADIAZINE SULFADIAZINE 500MG TABLET ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-20MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 2.5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-20MG CAPSULE P A Therapeutic Class Brand Name Status Generic Name Strength Form ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-40MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-40MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 10MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 20MG CAPSULE Acne Agents, Systemic ACCUTANE
    [Show full text]
  • 18 December 2020 – to Date)
    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
    [Show full text]
  • Piriformis Syndrome: the Literal “Pain in My Butt” Chelsea Smith, PTA
    Piriformis Syndrome: the literal “pain in my butt” Chelsea Smith, PTA Aside from the monotony of day-to-day pains and annoyances, piriformis syndrome is the literal “pain in my butt” that may not go away with sending the kids to grandmas and often takes the form of sciatica. Many individuals with pain in the buttock that radiates down the leg are experiencing a form of sciatica caused by irritation of the spinal nerves in or near the lumbar spine (1). Other times though, the nerve irritation is not in the spine but further down the leg due to a pesky muscle called the piriformis, hence “piriformis syndrome”. The piriformis muscle is a flat, pyramidal-shaped muscle that originates from the front surface of the sacrum and the joint capsule of the sacroiliac joint (SI joint) and is located deep in the gluteal tissue (2). The piriformis travels through the greater sciatic foramen and attaches to the upper surface of the greater trochanter (or top of the hip bone) while the sciatic nerve runs under (and sometimes through) the piriformis muscle as it exits the pelvis. Due to this close proximity between the piriformis muscle and the sciatic nerve, if there is excessive tension (tightness), spasm, or inflammation of the piriformis muscle this can cause irritation to the sciatic nerve leading to symptoms of sciatica (pain down the leg) (1). Activities like sitting on hard surfaces, crouching down, walking or running for long distances, and climbing stairs can all increase symptoms (2) with the most common symptom being tenderness along the piriformis muscle (deep in the gluteal region) upon palpation.
    [Show full text]
  • Pexion, Imepitoin
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pexion 100 mg tablets for dogs Pexion 400 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Active substance: Imepitoin 100 mg Imepitoin 400 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets White, oblong, half-scored tablets with embedded logo “I 01” (100 mg) or “I 02” (400 mg) on one side. The tablet can be divided into equal halves. 4. CLINICAL PARTICULARS 4.1 Target species Dog 4.2 Indications for use, specifying the target species For the reduction of the frequency of generalised seizures due to idiopathic epilepsy in dogs for use after careful evaluation of alternative treatment options. 4.3 Contraindications Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in dogs with severely impaired hepatic function, severe renal or severe cardiovascular disorders (see section 4.7). 4.4 Special warnings The pharmacological response to imepitoin may vary and efficacy may not be complete. Nevertheless imepitoin is considered to be a suitable treatment option in some dogs because of its safety profile (see section 5.1). On treatment, some dogs will be free of seizures, in other dogs a reduction of the number of seizures will be observed, whilst others may be non-responders. In non-responders, an increase in seizure frequency may be observed. Should seizures not be adequately controlled, further diagnostic measures and other antiepileptic treatment should be considered. The benefit/risk assessment for the individual dog should take into account the details in the product literature.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Piriformis Syndrome Is Overdiagnosed 11 Robert A
    American Association of Neuromuscular & Electrodiagnostic Medicine AANEM CROSSFIRE: CONTROVERSIES IN NEUROMUSCULAR AND ELECTRODIAGNOSTIC MEDICINE Loren M. Fishman, MD, B.Phil Robert A.Werner, MD, MS Scott J. Primack, DO Willam S. Pease, MD Ernest W. Johnson, MD Lawrence R. Robinson, MD 2005 AANEM COURSE F AANEM 52ND Annual Scientific Meeting Monterey, California CROSSFIRE: Controversies in Neuromuscular and Electrodiagnostic Medicine Loren M. Fishman, MD, B.Phil Robert A.Werner, MD, MS Scott J. Primack, DO Willam S. Pease, MD Ernest W. Johnson, MD Lawrence R. Robinson, MD 2005 COURSE F AANEM 52nd Annual Scientific Meeting Monterey, California AANEM Copyright © September 2005 American Association of Neuromuscular & Electrodiagnostic Medicine 421 First Avenue SW, Suite 300 East Rochester, MN 55902 PRINTED BY JOHNSON PRINTING COMPANY, INC. ii CROSSFIRE: Controversies in Neuromuscular and Electrodiagnostic Medicine Faculty Loren M. Fishman, MD, B.Phil Scott J. Primack, DO Assistant Clinical Professor Co-director Department of Physical Medicine and Rehabilitation Colorado Rehabilitation and Occupational Medicine Columbia College of Physicians and Surgeons Denver, Colorado New York City, New York Dr. Primack completed his residency at the Rehabilitation Institute of Dr. Fishman is a specialist in low back pain and sciatica, electrodiagnosis, Chicago in 1992. He then spent 6 months with Dr. Larry Mack at the functional assessment, and cognitive rehabilitation. Over the last 20 years, University of Washington. Dr. Mack, in conjunction with the Shoulder he has lectured frequently and contributed over 55 publications. His most and Elbow Service at the University of Washington, performed some of the recent work, Relief is in the Stretch: End Back Pain Through Yoga, and the original research utilizing musculoskeletal ultrasound in order to diagnose earlier book, Back Talk, both written with Carol Ardman, were published shoulder pathology.
    [Show full text]
  • 1-(4-Amino-Cyclohexyl)
    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
    [Show full text]
  • Evaluation of Pexion® (Imepitoin) for Treatment of Storm Anxiety in Dogs: a Randomised, Double-Blind, Placebo-Controlled Trial
    Received: 20 July 2020 Revised: 7 October 2020 Accepted: 3 December 2020 DOI: 10.1002/vetr.18 ORIGINAL RESEARCH Evaluation of Pexion® (imepitoin) for treatment of storm anxiety in dogs: A randomised, double-blind, placebo-controlled trial Irina Perdew1 Carrie Emke1 Brianna Johnson1 Vaidehi Dixit2 Yukun Song2 Emily H. Griffith2 Philip Watson3 Margaret E. Gruen1 1 Department of Clinical Sciences, North Abstract Carolina State University College of Background: While often grouped with other noise aversions, fearful Veterinary Medicine, Raleigh, North Carolina, USA behaviour during storms is considered more complex than noise aversion 2 Department of Statistics, North Carolina alone. The objective here was to assess the effect of imepitoin for the treat- State University College of Sciences, Raleigh, ment of storm anxiety in dogs. North Carolina, USA Methods: In this double-blind, placebo-controlled randomised study, eligible 3 Ingelheim am Rhein, Boehringer-Ingelheim dogs completed a baseline then were randomised to receive either imepitoin Vetmedica GmbH, Ludwigshafen am Rhein, (n = 30; 30 mg/kg BID) or placebo (n = 15) for 28 days. During storms, owners Germany rated their dog’s intensity for 16 behaviours using a Likert scale. Weekly, own- Correspondence ers rated intensity and frequency of these behaviours. Summary scores were Margaret E. Gruen, Department of Clinical compared to baseline and between groups. Sciences, North Carolina State University Results and Conclusions: Imepitoin was significantly superior to placebo in College of Veterinary Medicine, 1060 William Moore Drive, Raleigh NC 27607, USA. storm logs and weekly surveys for weeks 2 and 4, and in the end-of-study sur- Email: [email protected] vey.
    [Show full text]
  • Lumbosacral Plexus Entrapment Syndrome. Part One: a Common Yet Little-Known Cause of Chronic Pelvic and Lower Extremity Pain
    3-A Running head: ANAESTHESIA, PAIN & INTENSIVE CARE www.apicareonline.com ORIGINAL ARTICLE Lumbosacral plexus entrapment syndrome. Part one: A common yet little-known cause of chronic pelvic and lower extremity pain Kjetil Larsen, CES, George C. Chang Chien, D O2 ABSTRACT Corrective exercise specialist, Training & Rehabilitation, Oslo Lumbosacral plexus entrapment syndrome (LPES) is a little-known but common cause Norway of chronic lumbopelvic and lower extremity pain. The lumbar plexus, including the 2 Director of pain management, lumbosacral tunks emerge through the fibers of the psoas major, and the proximal Ventura County Medical Center, sciatic nerve beneath the piriformis muscles. Severe weakness of these muscles may Ventura, CA 93003, USA. lead to entrapment plexopathy, resulting in diffuse and non-specific pain patterns Correspondence: Kjetil Larsen, CES, Corrective throughout the lumbopelvic complex and lower extremities (LPLE), easily mimicking Exercise Specialist, Training & other diagnoses and is therefore likely to mislead the interpreting clinician. It is a Rehabilitation, Oslo Norway; pathology very similar to that of thoracic outlet syndrome, but for the lower body. This Kjetil@trainingandrehabilitation. two part manuscript series was written in an attempt to demonstrate the existence, com; pathophysiology, diagnostic protocol as well as interventional strategy for LPES, and Tel.: +47 975 45 192 its efficacy. Received: 23 November 2018, Reviewed & Accepted: 28 Key words: Pelvic girdle; Pain, Pelvic girdle; Lumbosacral plexus entrapment syndrome; February 2019 Piriformis syndrome; Nerve entrapment; Double-crush; Pain, Chronic; Fibromyalgia Citation: Larsen K, Chien GCC. Lumbosacral plexus entrapment syndrome. Part one: A common yet little-known cause of chronic pelvic and lower extremity pain.
    [Show full text]
  • Idiopathic Epilepsy in Dogs – Part One: Patient Approach
    Vet Times The website for the veterinary profession https://www.vettimes.co.uk Idiopathic epilepsy in dogs – part one: patient approach Author : Jacques Penderis, Holger Volk Categories : Vets Date : February 9, 2015 Dogs with recurrent epileptic seizures, and where no interictal neurological deficits or abnormalities on routine diagnostic tests are evident, have traditionally been defined as having “idiopathic epilepsy”. Rather than being a specific, single diagnosis, it is probable idiopathic epilepsy represents a complex interplay between genetic predisposition and intrinsic and extrinsic environmental factors, and the term “presumed genetic” has also been suggested to define these patients. A genetic basis for idiopathic epilepsy has been proposed in a number of breeds, including the golden retriever, Labrador retriever, Bernese mountain dog, Irish wolfhound, English springer spaniel, Keeshond, Hungarian vizsla, standard poodle, border collie and Finnish spitz (Viitmaa et al, 2013) and a possible susceptibility locus for epileptic seizures has been characterised in the Belgian shepherd dog (Seppälä et al, 2012). Reflecting its importance in veterinary medicine, idiopathic epilepsy is reported as the most common chronic neurological disease in dogs, with a prevalence of around 0.6 per cent in first opinion practice. Generalised seizures (where there is impairment of consciousness) are the most common type of epileptic seizure in dogs, while partial seizures appear to be relatively more common in cats; this, in part, represents the tendency for dogs with idiopathic epilepsy to have generalised seizures, or focal seizures with rapid secondary generalisation. The accurate description of generalised seizures in a patient with suspected idiopathic epilepsy is important, firstly to differentiate the episodes from other causes of collapse (for example, syncope) and secondly because the presence of generalised seizures is one of the criteria for making a diagnosis of idiopathic epilepsy.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant Et Al
    US 2010.0143507A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant et al. (43) Pub. Date: Jun. 10, 2010 (54) CARBOXYLIC ACID INHIBITORS OF Publication Classification HISTONE DEACETYLASE, GABA (51) Int. Cl. TRANSAMINASE AND SODIUM CHANNEL A633/00 (2006.01) A 6LX 3/553 (2006.01) A 6LX 3/553 (2006.01) (75) Inventors: Thomas G. Gant, Carlsbad, CA A63L/352 (2006.01) (US); Sepehr Sarshar, Cardiff by A6II 3/19 (2006.01) the Sea, CA (US) C07C 53/128 (2006.01) A6IP 25/06 (2006.01) A6IP 25/08 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) GLOBAL PATENT GROUP - APX (52) U.S. Cl. .................... 424/722:514/211.13: 514/221; 10411 Clayton Road, Suite 304 514/456; 514/557; 562/512 ST. LOUIS, MO 63131 (US) (57) ABSTRACT Assignee: AUSPEX The present invention relates to new carboxylic acid inhibi (73) tors of histone deacetylase, GABA transaminase, and/or PHARMACEUTICALS, INC., Sodium channel activity, pharmaceutical compositions Vista, CA (US) thereof, and methods of use thereof. (21) Appl. No.: 12/632,507 Formula I (22) Filed: Dec. 7, 2009 Related U.S. Application Data (60) Provisional application No. 61/121,024, filed on Dec. 9, 2008. US 2010/014.3507 A1 Jun. 10, 2010 CARBOXYLIC ACID INHIBITORS OF HISTONE DEACETYLASE, GABA TRANSAMNASE AND SODIUM CHANNEL 0001. This application claims the benefit of priority of Valproic acid U.S. provisional application No. 61/121,024, filed Dec. 9, 2008, the disclosure of which is hereby incorporated by ref 0004 Valproic acid is extensively metabolised via erence as if written herein in its entirety.
    [Show full text]